The non-small cell lung cancer clinical trial analysis report delivers important insights into ongoing research of 120+ ...
Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients ...
Results of a new study conclude that a pathology tool powered by artificial intelligence can predict whether a patient with ...
OPDIVO is a prescription medicine used in combination with YERVOY as a first treatment to treat adults with cancer of the ...
First-line zongertinib showed antitumor activity in treatment-naive patients with advanced or metastatic HER2-mutant ...
Learn how G-CSF and trilaciclib help prevent febrile neutropenia in extensive-stage SCLC, with NCCN-backed timing tips and ...
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced clinical data indicating zocilurtatug pelitecan (zoci, formerly ZL-1310), a DLL3-targeting antibody-drug conjugate (ADC), provides rapid and ...
Exceptional measures of efficacy observed in THIO-101 Phase 2 trial to date include disease control, response rates, and ...
The KRAS p.G12D variant occurs in 5% of patients with non–small-cell lung cancer (NSCLC) and is the most common substitution variant in pancreatic ductal adenocarcinoma, occurring in 40% of patients, ...
Morning Overview on MSN
New AI tool aims to predict small cell lung cancer treatment response
Researchers have built an AI-powered pathology tool designed to predict whether small cell lung cancer patients will respond ...
Researchers from The University of Texas MD Anderson Cancer Center will present breakthrough studies at the American Association for Cancer Research (AACR) Annual Meeting 2026.
The Scottish Medicines Consortium has approved osimertinib for adults with unresectable stage III EGFR-mutant NSCLC whose disease has not progressed after platinum-based chemoradiation.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results